NOV 4

Missing Data and Sensitivity Analyses presented by Abel Eshete, FDA

Statistical Considerations for Surrogate Endpoint Evaluation presented by Feng Li, FDA

Break

Panel Discussion: The Impact of Artificial Intelligence in Biopharmaceutical Statistics

Panelists:

Vipin Arora, Pacira Biosciences –

CV Damaraju, Johnson and Johnson –

Melvin Munsaka, AbbVie –

Robert Perera, Virginia Commonwealth University